亨廷顿病中的β-阻塞效应:对临床解释的注意事项
N Ahmad Aziz1,2, Daniel Claassen3, Åsa Petersén4,5
1German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Journal of Huntington's disease
|December 15, 2025
概括
尽管最近有建议,但β抑制剂可能不会减缓亨廷顿病 (HD) 的进展. 由于潜在的风险和关于它们对疾病影响的相互矛盾的证据,进一步的研究至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 最近的回顾性分析表明,β抑制剂可能会减缓亨廷顿病 (HD) 的进展.
- 这种基于观测子集的分析有局限性,包括偏见和混因素.
研究的目的:
- 批判性地评估证据,表明β-阻断剂会影响HD的进展.
- 在临床推之前强调需要谨慎和进一步严格调查.
主要方法:
- 对Enroll HD数据的回顾性分析的审查.
- 考虑一项先前的门德尔随机化研究.
- 评估与HD患者使用β-阻断剂相关的潜在风险和混因素.
主要成果:
- 追溯分析的发现是基于小的,潜在的偏见子集.
- 一项门德尔随机化研究发现,β-阻断剂和HD发病之间没有因果关系.
- 荷尔蒙病患者的高血压率较低,以及β-阻塞剂 (抑郁症,心肌梗塞) 的风险令人担忧.
结论:
- 建议β-阻断剂减缓HD进展需要高度谨慎.
- 相互矛盾的证据和潜在的危害需要严格的实验和临床试验.
- 目前还不能对在HD中使用β-阻断剂做出临床建议.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Heart Failure Drugs: β-Blockers
729
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
729
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Antihypertensive Drugs: Types of β-Blockers
1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K


